8 completed, 3 not yet recruiting, 1 recruiting. 4 Phase 1, 4 Phase 3, 2 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Not yet recruiting 1 |
| Phase 3 | 4 | Completed 4 |
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow chiglitazar: new trials by email Literature Review of chiglitazar trials Research Report on chiglitazar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets Chiglitazar/Metformin extended-release tablets under fasting conditions, Chiglitazar/Metformin extended-release tablets after a high-fat meal, multiple-dose of Chiglitazar/Metformin extended-release tablets - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Not yet recruiting | Chipscreen Biosciences, Ltd. | 28 | 2026-10-08 | 2026-04-06 |
| Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes SGLT-2 inhibitor and Chiglitazar, SGLT-2 inhibitor and Other Oral Antidiabetic Drugs (OADs) - T2DM (Type 2 Diabetes Mellitus) | Not yet recruiting | Chipscreen Biosciences, Ltd. | 3550 | 2026-07-18 | 2026-05-12 | |
| Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1, Chiglitazar tablet, dose 1, Metformin extended-release tablet, dose 1 - T2DM (Type 2 Diabetes Mellitus) | Not applicable | Completed | Chipscreen Biosciences, Ltd. | 64 | 2026-07-09 | 2026-09-23 |
| A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus Chiglitazar Placebo, Chiglitazar, vitamin E - MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus) | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 300 | 2026-01-01 | 2026-06-03 |
| The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis Chiglitazar 64mg, Placebo - Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis | Not applicable | Not yet recruiting | Beijing Friendship Hospital | 195 | 2025-02-05 | 2025-01-15 |
| Chiglitazar/Metformin in Non-obese Women With PCOS Chiglitazar, Metformin - Polycystic Ovary Syndrome, Chiglitazar | Phase 2 / Phase 3 | Completed | Shengjing Hospital | 55 | 2023-11-15 | 2025-01-01 |
| Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects. Chiglitazar, Empagliflozin, Atorvastatin - T2DM | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 48 | 2023-02-17 | 2023-06-15 |
| Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function Chiglitazar - Hepatic Impairment | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 24 | 2022-12-03 | 2024-05-28 |
| Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function Chiglitazar - Renal Impairment | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 24 | 2022-11-20 | 2024-05-28 |
| Chiglitazar Added to Metformin for Type 2 Diabetes Chiglitazar 32mg, Chiglitazar 48mg, Placebo - Type 2 Diabetes | Phase 3 | Completed | Chipscreen Biosciences, Ltd. | 533 | 2021-07-06 | 2024-07-15 |
| Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients Chiglitazar, Sitagliptin - Type 2 Diabetes | Phase 3 | Completed | Chipscreen Biosciences, Ltd. | 740 | 2014-09-01 | 2019-10-25 |
| Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients Chiglitazar, Placebo - Type 2 Diabetes | Phase 3 | Completed | Chipscreen Biosciences, Ltd. | 535 | 2014-06-01 | 2019-10-25 |
Diabetes Mellitus, Type 2 (7) · Diabetes Mellitus (1) · Polycystic Ovary Syndrome (1) · Renal Insufficiency (1)
Chipscreen Biosciences, Ltd. (9) · Beijing Friendship Hospital (1) · Shanghai Jiao Tong University School of Medicine (1) · Shengjing Hospital (1)
China (10)
LiYan Miao (2) · Hai Li, professor (1) · Hongrong Xu (1) · Linong Ji, Dr. (1) · Linong Ji, Prof. (1) · Weiping Jia, Dr. (1)
PMID 35547000, PMID 36654286, PMID 36654287, PMID 38162801, PMID 40842343, PMID 41331576, PMID 42148367, PMID 42150836